S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CTMX CytomX Therapeutics Inc

0.87

-0.005 (-0.57%)

Jan 31 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more CytomX Therapeutics Charts.

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more CytomX Therapeutics Charts.

CytomX Therapeutics Inc News

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Wednesday 8 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 6 January 2025 (4 weeks ago) • Edgar (US Regulatory)

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Monday 6 January 2025 (4 weeks ago) • GlobeNewswire Inc.

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Wednesday 27 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Thursday 7 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Thursday 31 October 2024 (3 months ago) • GlobeNewswire Inc.

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
Monday 9 September 2024 (5 months ago) • GlobeNewswire Inc.

CytomX Therapeutics to Present at Upcoming September Investor Conferences
Wednesday 4 September 2024 (5 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 August 2024 (5 months ago) • Edgar (US Regulatory)

More CytomX Therapeutics Inc News Articles

Northwest Biotherapeutics (QB)

Bioelectronics (PK)

Lightwave Logic

North Bay Resources (PK)

Fannie Mae (QB)

Elite Pharmaceuticals (QB)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions